Product Center
The First Phase of The Vaccine Industrialization Project Was Successfully Completed
- Categories:Industry news
- Author:
- Origin:
- Time of issue:2017-08-30
- Views:
(Summary description)The human vaccine industrialization project of Ab&B Bio-Tech Co., Ltd. (JS) covers an area of 70 acres (approx. 46,666 square meters), with a planned construction area of 50,000 square meters. The first-phase construction projects include: an R&D complex building, production workshop No. 1, an animal room, and a central laboratory.
The First Phase of The Vaccine Industrialization Project Was Successfully Completed
(Summary description)The human vaccine industrialization project of Ab&B Bio-Tech Co., Ltd. (JS) covers an area of 70 acres (approx. 46,666 square meters), with a planned construction area of 50,000 square meters. The first-phase construction projects include: an R&D complex building, production workshop No. 1, an animal room, and a central laboratory.
- Categories:Industry news
- Author:
- Origin:
- Time of issue:2017-08-30 10:57
- Views:
The human vaccine industrialization project of Ab&B Bio-Tech Co., Ltd. (JS) covers an area of 70 acres (approx. 46,666 square meters), with a planned construction area of 50,000 square meters. The first-phase construction projects include: an R&D complex building, production workshop No. 1, an animal room, and a central laboratory. The single-building facility, with a total area of 30,000 square meters, was successfully completed on August 30, 2017, and then entered the stage of interior decoration and process construction to prepare for clinical trials in 2018.
Relevant information
-
The Launch Meeting of Phase I/II Clinical Trial for Recombinant Herpes Zoster Vaccine (CHO Cell) was successfully heldRecently, the Phase I/II clinical trial launch meeting for the recombinant herpes zoster vaccine (CHO cell), co-developed by Ab&B Bio-Tech CO., LTD. JS. and Yither Biotech (Shanghai) Co., Ltd., was successfully held in Henan, and the first-in-human (FIH) dosing was successfully completed. - Ab&B Bio and Yither Bio Have Both Obtained Qualification Certification! 12-30
- Kickoff Meeting for Clinical Research on Quadrivalent Influenza Virus Subunit Vaccine in Children with Nephrotic Syndrome Successfully Held 12-25
- IND Application for Influenza Virus Subunit Vaccine (Adjuvanted) Approved 10-30
- The Application for the Marketing of Trivalent Influenza Virus Subunit Vaccine has been Accepted! 10-08
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
